#USA #New York #Securities Fraud #Pomerantz LLP #Immutep Limited

Class Action Suit Against Immutep Limited

The Pomerantz Law Firm recently announced its initiation of a class action lawsuit against Immutep Limited, a company listed on NASDAQ as IMMP. The firm is reaching out to investors who have incurred losses due to potential securities fraud or unlawful business practices attributed to Immutep and certain of its executives.

What You Need to Know

If you're an investor who purchased or otherwise acquired shares of Immutep during the class period, this lawsuit may directly affect you. Investors are invited to contact Danielle Peyton at Pomerantz Law Firm for more information and assistance in joining the class action. It's important for affected individuals to act swiftly, as the deadline to request the court to appoint them as Lead Plaintiff is July 6, 2026.

Background of the Case

The firm highlights significant developments surrounding Immutep in recent months. Notably, on March 13, 2026, the company announced the discontinuation of its Phase III clinical trial, TACTI-004, which was evaluating eftilagimod alfa ('efti') in patients with non-small cell lung cancer. This decision was made following a planned interim futility analysis conducted by the Independent Data Monitoring Committee (IDMC). The IDMC reviewed the trial's safety and efficacy data and made the recommendation to cease enrollment in light of subpar results.

In response to the distressing news from Immutep, the price of the company's American Depositary Receipt (ADR) plummeted by 82.44%, falling to $0.48 per share—a stark reminder of the volatility associated with biotech investments and the critical importance of transparency in reporting clinical trial outcomes.

Legal Implications and Next Steps

The class action lawsuit filed by Pomerantz posits that there could be wrongdoing on the part of Immutep and its officers regarding their handling of investor relations and disclosures. Investors are encouraged to reach out for legal support, especially those who might qualify to become Lead Plaintiffs in this case, significantly influencing the outcome of the proceedings.

About Pomerantz LLP

Founded over 85 years ago, Pomerantz LLP is recognized as a leading firm specializing in securities, corporate, and antitrust class litigation. Often referred to as the pioneer in the realm of securities class actions, the firm continues to advocate vigorously for investors' rights. This partnership, which boasts offices in major cities like New York, Chicago, and London, has successfully recovered significant financial settlements for its clients over the years.

For further details on how to participate in this class action or to get a copy of the complaint, interested parties can visit Pomerantz Law Firm's website. Inquiries can also be directed to Danielle Peyton via email or phone.

It's essential for investors to remain informed and proactive about their legal rights, especially in light of recent negative events that may impact their financial well-being. Act now to ensure your voice is heard in this pivotal case.